Biognostik Gesellschaft fur biomolekulare Diagnostik mbH
Patent Owner
Stats
- 3 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Apr 22, 2014 most recent publication
Details
- 3 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 109 Total Citation Count
- Jul 06, 1994 Earliest Filing
- 8 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
7667027 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β)ExpiredDec 29, 06Feb 23, 10[C07H]
7563778 Antisense oligonucleotide preparation methodExpiredNov 10, 04Jul 21, 09[C11Q, C07H, A01N, C12P]
7326783 Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasmsExpiredJul 06, 94Feb 05, 08[C07H]
2006/0252,716 Method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia"AbandonedMar 10, 01Nov 09, 06[A61K]
2003/0186,906 Mixture comprising an inhibitor or suppresor of a gene and a molecule binding to an expression product of that geneAbandonedOct 31, 02Oct 02, 03[A61K]
2003/0040,499 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta)AbandonedMay 16, 02Feb 27, 03[A61K, C07H]
6365345 Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a roleExpiredAug 15, 96Apr 02, 02[C07H, C12Q, C12N]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
